Literature DB >> 10543507

Hemi-Fontan procedure for hypoplastic left heart syndrome: outcome and suitability for Fontan.

W I Douglas1, C S Goldberg, R S Mosca, I H Law, E L Bove.   

Abstract

BACKGROUND: Following the Norwood procedure for hypoplastic left heart syndrome (HLHS), pulmonary artery distortion and hypoplasia are common and may negatively impact late outcome. The hemi-Fontan procedure (HFP) augments the central pulmonary arteries and establishes a connection between the right atrial/superior vena cava junction and the pulmonary arteries, while excluding the inferior vena cava.
METHODS: The hospital records of all 114 patients undergoing a HFP for HLHS between August 1993 and April 1998 were reviewed to assess patient, procedural, and morphologic determinations of outcome. The results of cardiac catheterization, Doppler/echocardiography, 12 lead electrocardiograms, hospital and subsequent course, as well as suitability and outcome for the Fontan procedure were analyzed.
RESULTS: Mean age was 5.4 months (range 1.5 to 15 months). Right ventricular function was normal in 95 patients, moderately depressed in 14, and severely depressed in five. Tricuspid regurgitation was absent or mild in 91 patients, moderate in 13, and severe in 10. Concomitant procedures included left superior vena cava to pulmonary artery anastomosis (12), tricuspid valve repair (10), pulmonary artery stent placement (3), coarctation repair (2), and aortic pseudoaneurysm repair (1). Hospital survival was 112/114, 98% (95% confidence interval [CI]: 95% to 100%). There were two late deaths, one noncardiac. Sinus rhythm is present in 105 patients (92%, 95% CI: 87% to 97%). To date, 79 of these patients have undergone the Fontan procedure with 74 survivors (94%, 95% CI: 89% to 99%).
CONCLUSIONS: The HFP may be performed with excellent results for HLHS. It effectively augments the central pulmonary arteries while preserving sinus rhythm in the majority. In addition, the HFP facilitates the subsequent Fontan procedure and has significantly improved the overall outcome.

Entities:  

Mesh:

Year:  1999        PMID: 10543507     DOI: 10.1016/s0003-4975(99)00915-7

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  16 in total

1.  Hypoplastic Left Heart Syndrome.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-12

2.  The lateral tunnel Fontan procedure for hypoplastic left heart syndrome: results of 100 consecutive patients.

Authors:  J C Hirsch; R G Ohye; E J Devaney; C S Goldberg; E L Bove
Journal:  Pediatr Cardiol       Date:  2007 Nov-Dec       Impact factor: 1.655

3.  Predictors of Prolonged Hospital Length of Stay Following Stage II Palliation of Hypoplastic Left Heart Syndrome (and Variants): Analysis of the National Pediatric Cardiology Quality Improvement Collaborative (NPC-QIC) Database.

Authors:  Carissa M Baker-Smith; Sara W Goldberg; Geoffrey L Rosenthal
Journal:  Pediatr Cardiol       Date:  2015-06-03       Impact factor: 1.655

4.  Impact of pre-stage II hemodynamics and pulmonary artery anatomy on 12-month outcomes in the Pediatric Heart Network Single Ventricle Reconstruction trial.

Authors:  Ranjit Aiyagari; John F Rhodes; Peter Shrader; Wolfgang A Radtke; Varsha M Bandisode; Lisa Bergersen; Matthew J Gillespie; Robert G Gray; Lin T Guey; Kevin D Hill; Russel Hirsch; Dennis W Kim; Kyong-Jin Lee; Andrew N Pelech; Jeremy Ringewald; Cheryl Takao; Julie A Vincent; Richard G Ohye
Journal:  J Thorac Cardiovasc Surg       Date:  2013-12-12       Impact factor: 5.209

5.  Staged surgical management of hypoplastic left heart syndrome: a single institution 12 year experience.

Authors:  S P McGuirk; M Griselli; O F Stumper; E M Rumball; P Miller; R Dhillon; J V de Giovanni; J G Wright; D J Barron; W J Brawn
Journal:  Heart       Date:  2005-06-06       Impact factor: 5.994

Review 6.  Hypoplastic left heart syndrome: current considerations and expectations.

Authors:  Jeffrey A Feinstein; D Woodrow Benson; Anne M Dubin; Meryl S Cohen; Dawn M Maxey; William T Mahle; Elfriede Pahl; Juan Villafañe; Ami B Bhatt; Lynn F Peng; Beth Ann Johnson; Alison L Marsden; Curt J Daniels; Nancy A Rudd; Christopher A Caldarone; Kathleen A Mussatto; David L Morales; D Dunbar Ivy; J William Gaynor; James S Tweddell; Barbara J Deal; Anke K Furck; Geoffrey L Rosenthal; Richard G Ohye; Nancy S Ghanayem; John P Cheatham; Wayne Tworetzky; Gerard R Martin
Journal:  J Am Coll Cardiol       Date:  2012-01-03       Impact factor: 24.094

7.  Hypoplastic left heart syndrome: Prognosis and management options.

Authors:  D S Fruitman
Journal:  Paediatr Child Health       Date:  2000-05       Impact factor: 2.253

8.  Risk factors for prolonged length of stay after the stage 2 procedure in the single-ventricle reconstruction trial.

Authors:  Steven M Schwartz; Minmin Lu; Richard G Ohye; Kevin D Hill; Andrew M Atz; Maryam Y Naim; Ismee A Williams; Caren S Goldberg; Alan Lewis; Frank Pigula; Peter Manning; Christian Pizarro; Paul Chai; Rachel McCandless; Carolyn Dunbar-Masterson; Jonathan R Kaltman; Kirk Kanter; Lynn A Sleeper; Julie V Schonbeck; Nancy Ghanayem
Journal:  J Thorac Cardiovasc Surg       Date:  2013-09-24       Impact factor: 5.209

9.  Design and rationale of a randomized trial comparing the Blalock-Taussig and right ventricle-pulmonary artery shunts in the Norwood procedure.

Authors:  Richard G Ohye; J William Gaynor; Nancy S Ghanayem; Caren S Goldberg; Peter C Laussen; Peter C Frommelt; Jane W Newburger; Gail D Pearson; Sarah Tabbutt; Gil Wernovsky; Lisa M Wruck; Andrew M Atz; Steve D Colan; James Jaggers; Brian W McCrindle; Ashwin Prakash; Michael D Puchalski; Lynn A Sleeper; Mario P Stylianou; Lynn Mahony
Journal:  J Thorac Cardiovasc Surg       Date:  2008-05-19       Impact factor: 5.209

10.  Hemodynamic performance of stage-2 univentricular reconstruction: Glenn vs. hemi-Fontan templates.

Authors:  Kerem Pekkan; Lakshimi P Dasi; Diane de Zélicourt; Kartik S Sundareswaran; Mark A Fogel; Kirk R Kanter; Ajit P Yoganathan
Journal:  Ann Biomed Eng       Date:  2008-11-06       Impact factor: 3.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.